BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35108727)

  • 1. Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant.
    Rubinstein JD; Lutzko C; Leemhuis T; Zhu X; Pham G; Ray L; Thomas S; Dourson C; Wilhelm J; Lane A; Cancelas JA; Lipps D; Ferrell J; Hanley PJ; Keller MD; Bollard CM; Wang YM; Davies SM; Nelson AS; Grimley MS
    Blood Adv; 2022 May; 6(9):2897-2907. PubMed ID: 35108727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young Adults.
    Galletta TJ; Lane A; Lutzko C; Leemhuis T; Cancelas JA; Khoury R; Wang YM; Hanley PJ; Keller MD; Bollard CM; Davies SM; Grimley MS; Rubinstein JD
    Transplant Cell Ther; 2023 May; 29(5):305-310. PubMed ID: 36736781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation.
    Tzannou I; Papadopoulou A; Naik S; Leung K; Martinez CA; Ramos CA; Carrum G; Sasa G; Lulla P; Watanabe A; Kuvalekar M; Gee AP; Wu MF; Liu H; Grilley BJ; Krance RA; Gottschalk S; Brenner MK; Rooney CM; Heslop HE; Leen AM; Omer B
    J Clin Oncol; 2017 Nov; 35(31):3547-3557. PubMed ID: 28783452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes following posttransplant virus-specific T-cell therapy in patients with sickle cell disease.
    Kinoshita H; Mandava M; Jensen-Wachspress M; Lang H; Joy E; Tanna J; McCann CD; O'Brien S; Burnett S; Shibli A; Hoq F; Bhatia M; Hanley PJ; Dávila Saldaña B; Mahadeo KM; Bollard CM; Keller MD; Abraham A
    Blood Adv; 2023 May; 7(10):2105-2116. PubMed ID: 36516084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies.
    Xuan L; Huang F; Fan Z; Zhou H; Zhang X; Yu G; Zhang Y; Liu C; Sun J; Liu Q
    J Hematol Oncol; 2012 Aug; 5():46. PubMed ID: 22856463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant.
    Jiang W; Clancy LE; Avdic S; Sutrave G; Street J; Simms R; McGuire HM; Patrick E; Chan AS; McCaughan G; Myers N; Micklethwaite KP; Antonenas V; Selim AG; Ritchie D; Bateman CM; Shaw PJ; Blyth E; Gottlieb DJ
    Blood Adv; 2022 Sep; 6(17):4949-4966. PubMed ID: 35819448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The time-dependent effects of early-onset Epstein-Barr viremia on adult acute leukemia patients following allo-HSCT with ATG-containing MAC regimen.
    Ke P; Zhang X; Liu S; Zhu Q; Ma X; Chen F; Tang X; Han Y; Fu Z; Chen S; Wu D; Qiu H; Zhou J; Bao X
    Ann Hematol; 2021 Jul; 100(7):1879-1889. PubMed ID: 33885923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk Factors and Utility of a Risk-Based Algorithm for Monitoring Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections in Pediatric Recipients after Allogeneic Hematopoietic Cell Transplantation.
    Rustia E; Violago L; Jin Z; Foca MD; Kahn JM; Arnold S; Sosna J; Bhatia M; Kung AL; George D; Garvin JH; Satwani P
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1646-1653. PubMed ID: 27252110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Ma CK; Blyth E; Clancy L; Simms R; Burgess J; Brown R; Deo S; Micklethwaite KP; Gottlieb DJ
    Cytotherapy; 2015 Oct; 17(10):1406-20. PubMed ID: 26349000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment.
    Keller MD; Hanley PJ; Chi YY; Aguayo-Hiraldo P; Dvorak CC; Verneris MR; Kohn DB; Pai SY; Dávila Saldaña BJ; Hanisch B; Quigg TC; Adams RH; Dahlberg A; Chandrakasan S; Hasan H; Malvar J; Jensen-Wachspress MA; Lazarski CA; Sani G; Idso JM; Lang H; Chansky P; McCann CD; Tanna J; Abraham AA; Webb JL; Shibli A; Keating AK; Satwani P; Muranski P; Hall E; Eckrich MJ; Shereck E; Miller H; Mamcarz E; Agarwal R; De Oliveira SN; Vander Lugt MT; Ebens CL; Aquino VM; Bednarski JJ; Chu J; Parikh S; Whangbo J; Lionakis M; Zambidis ET; Gourdine E; Bollard CM; Pulsipher MA
    Nat Commun; 2024 Apr; 15(1):3258. PubMed ID: 38637498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real world experience: Examining outcomes using letermovir for CMV prophylaxis in high-risk allogeneic hematopoietic stem cell patients in the setting of using T-cell depletion as GVHD prophylaxis.
    Dwabe S; Hsiao M; Ali A; Rodman J; Savitala-Damerla L; Nazaretyan S; Kimberly Schiff NP; Tam E; Ladha A; Woan K; Chaudhary P; Yaghmour G
    Transpl Immunol; 2023 Feb; 76():101769. PubMed ID: 36464218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk Factors for and the Clinical Impact of Cytomegalovirus and Epstein-Barr Virus Infections in Pediatric Recipients of TCR-α/β- and CD19-Depleted Grafts.
    Laberko A; Bogoyavlenskaya A; Shelikhova L; Shekhovtsova Z; Balashov D; Voronin K; Kurnikova E; Boyakova E; Raykina E; Brilliantova V; Pirumova V; Novichkova G; Maschan A; Maschan M
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):483-490. PubMed ID: 28039080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single exercise bout enhances the manufacture of viral-specific T-cells from healthy donors: implications for allogeneic adoptive transfer immunotherapy.
    Spielmann G; Bollard CM; Kunz H; Hanley PJ; Simpson RJ
    Sci Rep; 2016 May; 6():25852. PubMed ID: 27181409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Monitoring of early Epstein-Barr virus reactivation and preemptive therapy after allogeneic hematopoietic stem cell transplantation].
    Lu Y; Wu T; Cao XY; Wang JB; Sun Y; Zhao YL; DA WM; Ji SQ; Tong CR; Lu DP
    Zhonghua Nei Ke Za Zhi; 2011 May; 50(5):383-7. PubMed ID: 21624219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study.
    Cruz CR; Micklethwaite KP; Savoldo B; Ramos CA; Lam S; Ku S; Diouf O; Liu E; Barrett AJ; Ito S; Shpall EJ; Krance RA; Kamble RT; Carrum G; Hosing CM; Gee AP; Mei Z; Grilley BJ; Heslop HE; Rooney CM; Brenner MK; Bollard CM; Dotti G
    Blood; 2013 Oct; 122(17):2965-73. PubMed ID: 24030379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology and outcome for viremia in children undergoing bone marrow transplant: A retrospective cohort study.
    Silcock R; Mitchell K; Fraser C; Clark J
    Transpl Infect Dis; 2021 Aug; 23(4):e13580. PubMed ID: 33533068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD3
    Ramanathan S; Lum SH; Nademi Z; Carruthers K; Watson H; Flood T; Owens S; Williams E; Hambleton S; Gennery AR; Slatter M
    Transplant Cell Ther; 2023 Aug; 29(8):513.e1-513.e9. PubMed ID: 37279857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigenic competition in the generation of multi-virus-specific cell lines for immunotherapy of human cytomegalovirus, polyomavirus BK, Epstein-Barr virus and adenovirus infection in haematopoietic stem cell transplant recipients.
    Roubalová K; Němečková Š; Kryštofová J; Hainz P; Pumannová M; Hamšíková E
    Immunol Lett; 2020 Dec; 228():64-69. PubMed ID: 33031870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical outcomes of allogeneic hematopoietic stem cell transplantation patients with co-activation of cytomegalovirus and Epstein-Barr virus].
    Song T; Chen G; Zhang X; Xu Y; Chen J; Wang Y; Ye L; Xu J; Wu D; Miao J
    Zhonghua Yi Xue Za Zhi; 2014 Nov; 94(40):3135-9. PubMed ID: 25573307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-Reactivation of Cytomegalovirus and Epstein-Barr Virus Was Associated With Poor Prognosis After Allogeneic Stem Cell Transplantation.
    Zhou JR; Shi DY; Wei R; Wang Y; Yan CH; Zhang XH; Xu LP; Liu KY; Huang XJ; Sun YQ
    Front Immunol; 2020; 11():620891. PubMed ID: 33664733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.